Document Detail

Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.
MedLine Citation:
PMID:  7987979     Owner:  NLM     Status:  MEDLINE    
This study was undertaken to investigate the day-to-day pharmacokinetic variability of 5-fluorouracil (5FU) given as a continuous i.v. infusion concomitantly with cisplatin. Ten lung cancer patients were investigated during the first course of chemotherapy. All patients had advanced, previously untreated, inoperable non-small-cell lung cancer. They received continuous infusions of cisplatin given at 100 mg/m2 over 5 days and of 5FU given at 1 g/m2 daily from day 2 to day 5. Both drugs were infused i.v. for 24 h/day at a constant rate with a volumetric pump. Blood samples were drawn from day 2 to day 5, every 4 h from 8 a.m. to 8 p.m. and every 2 h during the night (8 p.m. to 8 a.m.). Plasma 5FU and FBAL concentrations were determined simultaneously by gas chromatography-mass spectrometry. Plasma 5FU concentrations varied widely over the 4-day treatment course for each patient. Despite continuous constant-rate 5FU administration, plasma 5FU concentrations were significantly lower between 8 a.m. and 8 p.m. than during the night. Mean plasma concentrations of 5FU and FBAL increased significantly from the 1st day (0.42 and 1.19 micrograms/ml for 5FU and FBAL, respectively) to the 4th day of 5FU infusion (0.67 and 1.78 micrograms/ml for 5FU and FBAL, respectively). Further study is warranted to elucidate the mechanisms of the observed increase in plasma 5FU concentrations as well as its relationship with cisplatin coadministration and to assess the clinical relevance of this plasma 5FU accumulation.
L Thiberville; P Compagnon; N Moore; G Bastian; M O Richard; M F Hellot; C Vincent; M M Kannass; S Dominique; C Thuillez
Related Documents :
25320369 - New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on t...
10089069 - Effect of pirarubicin for elderly patients with malignant lymphoma.
21088439 - A single-arm phase ii trial of first-line paclitaxel in combination with lapatinib in h...
2505879 - High dose chemotherapy with autologous hematopoietic stem cell support in the treatment...
21979289 - Diagnosis and treatment update: cholangiocarcinoma.
15330199 - Randomized phase ii study comparing mitomycin, cisplatin plus doxifluridine with cispla...
8683229 - Phase ii trial of paclitaxel and cisplatin in women with advanced breast cancer: an act...
21775129 - Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pr...
25032649 - American brain tumor association young investigator award 198 circulating tumor cells...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  35     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  1994  
Date Detail:
Created Date:  1995-01-12     Completed Date:  1995-01-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  64-70     Citation Subset:  IM    
Clinique Pneumologique, C.H.R.U. de Rouen, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / blood*,  drug therapy
Cisplatin / administration & dosage
Fluorouracil / administration & dosage,  blood,  pharmacokinetics*
Infusions, Intravenous
Lung Neoplasms / blood*,  drug therapy
Middle Aged
Time Factors
beta-Alanine / analogs & derivatives*,  blood,  pharmacokinetics
Reg. No./Substance:
107-95-9/beta-Alanine; 15663-27-1/Cisplatin; 3821-81-6/alpha-fluoro-beta-alanine; 51-21-8/Fluorouracil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkyl...
Next Document:  Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signal...